Igho Onakpoya – BMJ EBM Spotlight

Seven ways to ensure faster removal of harmful medicines

Posted on 13th December 20174th January 2018 by BMJ

Harmful medicines sometimes stay on the market for longer than they should. When that happens, people are unnecessarily exposed to medicines that may adversely affect their health. Igho Onakpoya The benefit-harm balance of new medicines is often not fully known at the time marketing licences are granted. More information about harms often becomes apparent […]

Rare adverse events in clinical trials: understanding the rule of three

Posted on 14th November 201721st November 2017 by BMJ

Investigators should report rare and very rare adverse events in clinical trials: Igho Onakpoya reports why it is important that all events are reported irrespective of their frequency. Even though they may not give a signal in any single trial, a meta-analysis could reveal potentially important drug-adverse event associations that might require further […]